AstraZeneca Gets FDA Nod for Maintenance Treatment of Schizophrenia
Posted on: Friday, 16 November 2007, 12:00 CST
AstraZeneca has said that the FDA has approved its once-daily Seroquel extended-release tablets for maintenance treatment of schizophrenia in adult patients.
The FDA approval for maintenance treatment of schizophrenia was based on clinical trial results in which patients who had responded to Seroquel for the treatment of schizophrenia for 16 weeks were randomized and either continued on Seroquel or were switched to placebo. The primary endpoint was the time from randomization to psychiatric relapse.
In the clinical trial supporting this approval, patients with schizophrenia who were treated with Seroquel experienced a significantly longer time to relapse, compared with patients receiving placebo. Patients receiving Seroquel demonstrated an 84% reduction in the relative risk of relapse. Results showed the estimated risk of relapse after six months was 14.3% in the Seroquel group versus 68.2% in the placebo group.
Mark Scott, executive director for development, AstraZeneca, said: "The clinical trial results provided compelling evidence for reducing the risk of relapse when these patients are treated with Seroquel."
Source: Datamonitor
Related Articles
- TRACON Pharmaceuticals Doses the First Patient in a Phase 1 Clinical Trial With Oral TRC102, An Inhibitor of Chemotherapy Resistance, in Combination With Alimta
- Micromet Enrolls First Patient in a Phase 1 Clinical Trial With MT110, the First BiTE Antibody for Treatment of Solid Tumors
- NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
- New Web Site Helps Patients Find Stanford Clinical Trials More Easily
- Medivation Announces Treatment of First Patient in Phase 1-2 Clinical Trial of MDV3100 in Hormone-Refractory Prostate Cancer
- ReceptoPharm Begins Phase IIb Human Clinical Trial for the Treatment of Adrenomyeloneuropathy
- Nutra Pharma Announces Final Approval to Begin Phase IIb Human Clinical Trial for the Treatment of Adrenomyeloneuropathy
- MedImmune Begins Dosing of Lupus Patients in Phase 1 Clinical Trial
- Medarex Announces Start of Dosing in Phase I Clinical Trial for the Treatment of Lupus
- GelStat Corporation Completes Patient Enrollment in Clinical Trial of GelStat Migraine in Triptan Users
 |
 |
User Comments (0)
RSS Feeds